Farther Finance Advisors LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 125.1% ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues. See why ...

Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) ...

The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.